Can you lose weight on the lowest dose of Wegovy?

The myth that 0.25mg 'doesn't count'

A lot of people assume the starter dose is purely ceremonial, that nothing useful is happening until you reach the higher numbers. That's understandable, but it misses something. Semaglutide is active at 0.25mg. GLP-1 receptors in the gut and brain respond to it from the first injection, slowing gastric emptying and beginning to dampen appetite signals. What the lowest dose lacks is potency sufficient to produce the full therapeutic effect seen in trials at 2.4mg.

The distinction matters. Some people do experience reduced hunger during their first four weeks and lose a small amount of weight. Others feel the GI side effects (nausea, occasional loose stools, mild fatigue) without much appetite change yet. Both responses are normal. Neither means treatment is working or failing; it means the titration schedule is doing what it is supposed to do. The 0.25mg effectiveness question deserves a more careful answer than a simple yes or no, and that answer lives in the trial data rather than in online anecdote.

The STEP 1 trial, published in the New England Journal of Medicine, recorded an average weight reduction of around 15% over 68 weeks at 2.4mg, but participants spent the majority of that time at doses above the starter level. The 0.25mg phase is the runway, not the flight.

What happens to weight as the dose increases

Wegovy's licensed titration moves in four-weekly steps: 0.25mg, then 0.5mg, then 1.0mg, then 1.7mg, then 2.4mg as the maintenance target. Each step up typically brings a more pronounced appetite effect, and the weight loss trajectory in trial populations steepened as doses increased. This is why a prescriber does not simply leave you at the lowest dose indefinitely.

If you are curious about what individual steps in the schedule tend to produce, the Wegovy dose guide covers the full titration picture. Similarly, the experience at 0.5mg (the second rung) is meaningfully different from the first, and the 0.5mg weight loss question has its own detail worth reading. Some people who feel little change at 0.25mg notice a clear shift at 0.5mg; that progression is part of the design.

The NHS notes that semaglutide works alongside a reduced-calorie diet and increased physical activity, the medicine is not a standalone intervention. NHS guidance on semaglutide sets out what to expect at each stage, and it is worth reading before or alongside treatment. Dose increases are a prescriber decision, not something to self-manage.

Can you stay at the lowest dose if it suits you?

Clinically, some people do remain on a lower dose for longer if a higher dose causes side effects that do not settle. That is a decision made with a prescriber, not a unilateral choice. The licensed maximum benefit is observed at 2.4mg, and NICE's recommendation for semaglutide under TA875 is built around reaching and maintaining that target dose within a supervised programme.

The question of staying long-term at the lowest dose is a real one that our prescribers hear regularly. In short: it is possible under certain clinical circumstances, but it is not the intended pathway and should not be approached as a cost-saving workaround. If the concern is whether the dose escalation feels manageable, that conversation belongs in a clinical consultation, not in a forum thread.

For context on where Wegovy sits among current weight-loss treatment options, the weight-loss treatments overview sets out what is licensed and how access works. If you are weighing whether to start, a free consultation with our prescribers is the place to have that conversation properly.

Side effects at the lowest dose

The most common side effects at 0.25mg are gastrointestinal: nausea, constipation, diarrhoea, indigestion. They are generally milder at the lower dose than at maintenance, though individual responses vary. Most people find they ease within the first couple of weeks as the body adapts. If you are wondering whether you can lose weight on 0.25mg of Wegovy while navigating these early side effects, the answer depends on how your body responds during those first four weeks. Starting slowly is precisely why the titration schedule exists.

The MHRA updated its guidance in January 2026 following a Drug Safety Update on GLP-1 receptor agonists, highlighting acute pancreatitis as an infrequent but serious risk: severe, persistent abdominal pain that may radiate to the back warrants urgent medical attention. This applies across all doses, not just higher ones. People who want to understand whether low dose Wegovy can produce weight loss will find that the evidence points to modest early changes for some, with more consistent results building as the titration progresses. Side effects at any stage can be reported directly to the MHRA via the Yellow Card scheme.

Under-18s are not licensed for Wegovy. Wegovy is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. A prescriber goes through all relevant contraindications before treatment is approved.